A Phase I/II study of nab-Paclitaxel plus S-1 therapy in previously treated patients with refractory advanced non-small-cell lung cancer
- Conditions
- Advanced non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000012966
- Lead Sponsor
- Depatment of Thoracic Oncology Osaka Medical Center for Cancer and Cardiovascular Diseases
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 45
Not provided
(1)Presencee of other active malignancy (2)SVC syndrome (3)Myocardial infarction, which was developed within six months (4)Liver chirrosis (5)With interstitial pneumonia or pulmonary fibrosis on a chest X-ray (6)Clinically significant drug allergy (7)With severe infection, gastrointestinal hemorrhage or cardiac diseases (8)With persistent diarrhea (9)With with intestinal paralysis or ileus (10)Diabetes with poor control (11)With pericardial effusion, pleural effusion and ascites in need of treatment of drainage (12)Patients received palliative radiotherapy for brain metastases and bone metastases, except for the primary lesion within 2weeks. (13)Symptomatic brain metastasis (14)Peripheral neuropathy of Grade2 or more (15)Positive serum HBs antigen (16)Uncontrolled psychiatric diseases (17)Pregnancy or lactating patients (18)with a history of hypersensitivity to nab-PTX, S-1, paclitaxel, or albumin (19)Others
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method